Emergent Biosolutions Inc.
A specialty biopharmaceutical company that makes medicines to protect against biological threats and opioid overdoses. Its best-known products include BioThrax, a vaccine against anthrax, and NARCAN, a nasal spray that reverses opioid overdoses and became the first naloxone product sold over the counter without a prescription. Founded in 1998 as BioPort, the company took over Michigan's anthrax vaccine facilities and later renamed itself Emergent BioSolutions, a nod to its role in helping people emerge from public health emergencies.
Granted 364.0K
Granted 470.2K · Bought 60.0K
Granted 467.1K · Bought 3.0K
Granted 328.4K · Sold 30.6K
Granted 188.9K
Granted 177.6K
Granted 192.1K
Granted 144.4K
Granted 166.8K
Granted 179.9K · Sold 4.0K
Granted 195.8K · Sold 35.0K
Granted 119.5K
Granted 94.1K
Granted 195.8K · Sold 66.1K
Granted 145.2K · Sold 23.9K
Granted 119.5K · Sold 14.3K
Granted 122.9K · Sold 22.3K
Granted 119.6K · Sold 23.3K
Granted 50.3K
Granted 119.5K · Sold 53.9K
Granted 37.6K
Granted 42.3K
Granted 8.4K
Granted 30.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| El-Hibri FuadDirector · 3 transactions | — | 4.64Mas of Dec 2021 | — | — | — |
| Kramer RobertPresident and CEO, Director · 16 transactions | +210.4% | 506.1Kas of Jun 2023 | 364.0K | — | — |
| Papa Joseph CPresident and CEO, Director · 4 transactions | — | 493.2K | 470.2K | 60.0K | — |
| Lindahl Richard SEVP, Chief Financial Officer · 35 transactions | +913.3% | 374.1K | 467.1K | 3.0K | — |
| Glessner ColeenEVP, Quality & Ethics, and CPL · 26 transactions | — | 202.2K | 328.4K | — | 30.6K |
| Fox Jennifer LynneEVP, Ext Aff, GC, Corp Sec · 18 transactions | — | 186.4Kas of Jul 2024 | 188.9K | — | — |
| Hartzel WilliamSVP, Bioservices · 17 transactions | — | 185.6K | 177.6K | — | — |
| Lowry Simon CSVP, R&D, CMO · 5 transactions | — | 177.9K | 192.1K | — | — |
| Havey AdamEVP, Business Operations · 16 transactions | +356.7% | 174.4Kas of Jun 2023 | 144.4K | — | — |
| Perl JessicaSVP, General Counsel, Corp Sec · 5 transactions | — | 165.3K | 166.8K | — | — |
| Williams Paul AnthonySVP, Products Business · 24 transactions | — | 162.1K | 179.9K | — | 4.0K |
| Fowler Neal FranklinDirector · 5 transactions | — | 160.8K | 195.8K | — | 35.0K |
| Harsanyi ZsoltChairman, Director · 5 transactions | +403.5% | 149.1K | 119.5K | — | — |
| Sullivan Louis WDirector · 4 transactions | +209.3% | 139.1Kas of Apr 2025 | 94.1K | — | — |
| DeGolyer Donald WDirector · 9 transactions | — | 130.7K | 195.8K | — | 66.1K |
| Richard RonaldDirector · 10 transactions | +830.3% | 123.8K | 145.2K | — | 23.9K |
| White Marvin LDirector · 6 transactions | +1215.1% | 113.8K | 119.5K | — | 14.3K |
| Dayal Sujata TyagiDirector · 8 transactions | — | 101.5K | 122.9K | — | 22.3K |
| Katkin KeithDirector · 7 transactions | — | 96.3K | 119.6K | — | 23.3K |
| Saran AtulEVP, Chief Strat & Dev Officer · 12 transactions | +93.6% | 86.6Kas of Feb 2023 | 50.3K | — | — |
| Zoon Kathryn CDirector · 16 transactions | +463.4% | 81.0K | 119.5K | — | 53.9K |
| Strei KatherineEVP, Chief HR Officer · 12 transactions | +96% | 62.8Kas of Feb 2023 | 37.6K | — | — |
| Hauer Jerome MDirector · 2 transactions | +278% | 57.5Kas of May 2023 | 42.3K | — | — |
| Joulwan George ADirector · 1 transaction | +26.6% | 40.2Kas of May 2022 | 8.4K | — | — |
| Fowler John D JrDirector · 2 transactions | — | 30.4K | 30.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -210.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.